Literature DB >> 28130210

Antenatal management in fetal and neonatal alloimmune thrombocytopenia: a systematic review.

Dian Winkelhorst1, Michael F Murphy2,3, Andreas Greinacher4, Nadine Shehata5,6, Taman Bakchoul4,7, Edwin Massey8, Jillian Baker9, Lani Lieberman10, Susano Tanael11, Heather Hume12, Donald M Arnold13, Shoma Baidya14, Gerald Bertrand15, James Bussel16, Mette Kjaer17,18, Cécile Kaplan19, Jens Kjeldsen-Kragh20, Dick Oepkes1, Greg Ryan21.   

Abstract

Several strategies can be used to manage fetal or neonatal alloimmune thrombocytopenia (FNAIT) in subsequent pregnancies. Serial fetal blood sampling (FBS) and intrauterine platelet transfusions (IUPT), as well as weekly maternal IV immunoglobulin infusion (IVIG), with or without additional corticosteroid therapy, are common options, but optimal management has not been determined. The aim of this systematic review was to assess antenatal treatment strategies for FNAIT. Four randomized controlled trials and 22 nonrandomized studies were included. Pooling of results was not possible due to considerable heterogeneity. Most studies found comparable outcomes regarding the occurrence of intracranial hemorrhage, regardless of the antenatal management strategy applied; FBS, IUPT, or IVIG with or without corticosteroids. There is no consistent evidence for the value of adding steroids to IVIG. FBS or IUPT resulted in a relatively high complication rate (consisting mainly of preterm emergency cesarean section) of 11% per treated pregnancy in all studies combined. Overall, noninvasive management in pregnant mothers who have had a previous neonate with FNAIT is effective without the relatively high rate of adverse outcomes seen with invasive strategies. This systematic review suggests that first-line antenatal management in FNAIT is weekly IVIG administration, with or without the addition of corticosteroids.
© 2017 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28130210     DOI: 10.1182/blood-2016-10-739656

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

Review 1.  Thrombocytopenia in pregnancy.

Authors:  Douglas B Cines; Lisa D Levine
Journal:  Blood       Date:  2017-06-21       Impact factor: 22.113

Review 2.  Thrombocytopenia in pregnancy.

Authors:  Douglas B Cines; Lisa D Levine
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 3.  Potential of Next-Generation Sequencing in Noninvasive Fetal Molecular Blood Group Genotyping.

Authors:  Sandra Wienzek-Lischka; Sandy Bachmann; Vanessa Froehner; Gregor Bein
Journal:  Transfus Med Hemother       Date:  2020-01-20       Impact factor: 3.747

4.  Preclinical evaluation of immunotherapeutic regimens for fetal/neonatal alloimmune thrombocytopenia.

Authors:  Huiying Zhi; Maria T Ahlen; Björn Skogen; Debra K Newman; Peter J Newman
Journal:  Blood Adv       Date:  2021-09-28

5.  Non-invasive risk-assessment and bleeding prophylaxis with IVIG in pregnant women with a history of fetal and neonatal alloimmune thrombocytopenia: management to minimize adverse events.

Authors:  Sandra Wienzek-Lischka; Angelika Sawazki; Harald Ehrhardt; Ulrich J Sachs; Roland Axt-Fliedner; Gregor Bein
Journal:  Arch Gynecol Obstet       Date:  2020-06-04       Impact factor: 2.344

6.  A case report of prenatal diagnosis of fetal alloimmune thrombocytopenia: A CARE-compliant article.

Authors:  Jing Fu; Ruojin Yao; Wenjing Yong
Journal:  Medicine (Baltimore)       Date:  2021-06-18       Impact factor: 1.817

Review 7.  Glanzmann Thrombasthenia: Perspectives from Clinical Practice on Accurate Diagnosis and Optimal Treatment Strategies.

Authors:  Natalie Mathews; Georges-Etienne Rivard; Arnaud Bonnefoy
Journal:  J Blood Med       Date:  2021-06-11

8.  IVIG-Associated Maternal Pancytopenia during Treatment for Neonatal Alloimmune Thrombocytopenia.

Authors:  Alyssa Herrmann; Benjamin J Samelson-Jones; Sami Brake; Renee Samelson
Journal:  AJP Rep       Date:  2017-09-29

9.  HIP (HPA-screening in pregnancy) study: protocol of a nationwide, prospective and observational study to assess incidence and natural history of fetal/neonatal alloimmune thrombocytopenia and identifying pregnancies at risk.

Authors:  C Ellen van der Schoot; Masja de Haas; Dian Winkelhorst; Thijs W de Vos; Marije M Kamphuis; Leendert Porcelijn; Enrico Lopriore; Dick Oepkes
Journal:  BMJ Open       Date:  2020-07-20       Impact factor: 2.692

10.  Placental Complement Activation in Fetal and Neonatal Alloimmune Thrombocytopenia: An Observational Study.

Authors:  Thijs W de Vos; Dian Winkelhorst; Hans J Baelde; Kyra L Dijkstra; Rianne D M van Bergen; Lotte E van der Meeren; Peter G J Nikkels; Leendert Porcelijn; C Ellen van der Schoot; Gestur Vidarsson; Michael Eikmans; Rick Kapur; Carin van der Keur; Leendert A Trouw; Dick Oepkes; Enrico Lopriore; Marie-Louise P van der Hoorn; Manon Bos; Masja de Haas
Journal:  Int J Mol Sci       Date:  2021-06-23       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.